HMHenry Ma

Henry Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henry Ma has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Coronary Plaque Phenotype in Ischemic Stroke Survivors: A Quantitative Coronary CT Angiography Comparison with Acute Myocardial Infarction and Stable Chest Pain

    by Rahul G. Muthalaly, Julian Giovannucci, Andrew Lin, Sean Tan, Nitesh Nerlekar, Adam J. Nelson, Damini Dey, Thanh Phan, Henry Ma, Stephen J. Nicholls

    Ischemic stroke survivors displayed a lower and more stable coronary plaque burden than matched participants with acute myocardial infarction or stable chest pain despite similar stenosis severity, suggesting that coronary CT angiography may improve risk stratification.

  • Open Access

    The Thrombectomy Dilemma in Stroke Patients With Active Cancer: To Treat or Not to Treat?

    by Yohanna Kusuma, Mikiya Beppu, Beom Joon Kim, Sung-Chun Tang, Mikito Hayakawa, Hiroshi Yamagami, Hiroyuki Kawano, Teruyuki Hirano, Shinichi Yoshimura, Hamidon Basri, et al.

    Endovascular thrombectomy for acute large-vessel occlusion in patients with active cancer remains a difficult clinical decision. Multiple cohort studies and meta-analyses indicate that, when standard imaging and clinical criteria are applied, reperfusion success is high and symptomatic intracranial hemorrhage is broadly comparable with non-cancer populations, arguing against categorical exclusion. At the same time, registries show lower 90-day functional independence and higher 90-day mortality in active-cancer cohorts—effects likely driven by malignancy-related systemic factors and pre-existing functional compromise rather than procedural harm. This narrative review synthesizes efficacy and safety signals, highlights decision-grade outcomes that are seldom reported—early neurological change, performance status around 90 days, and whether systemic anticancer therapy is started or resumed. It sets out a clinical–ethical–economic framework to support selection, consent, and aftercare, including a pragmatic pathway for under-resourced settings based on non-contrast computed tomography (CT) or single-phase CT angiography where advanced perfusion imaging or magnetic resonance imaging are unavailable. We outline an Asia–Pacific collaborative program designed to identify subgroups that may benefit from reperfusion and initiation of active cancer care.

  • Open Access

    Systolic Blood Pressure Trajectory and Outcomes in Acute Intracerebral Hemorrhage

    by Xia Wang, Thanh G. Phan, Xinwen Ren, Henry H. Ma, Qiang Li, Menglu Ouyang, Candice Delcourt, Xiaoying Chen, Jiguang Wang, Thompson G. Robinson, et al.

    Background and ObjectivesWhile moderate and rapid systolic blood pressure (SBP) lowering was associated with better functional outcomes after intracerebral hemorrhage (ICH), large reductions in SBP...


  • Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage

    by Isabel Charlotte Hostettler, Ana Ponciano, Duncan Wilson, Gareth Ambler, Aneesh B. Singhal, Andreas Charidimou, Catherine Elizabeth Arnold, Sebastián F. Ameriso, Federico Eberbach, Thanh G. Phan, et al.

    The most common cause of convexity subarachnoid hemorrhage (cSAH) in younger patients (younger than 60 years) is reversible cerebral vasoconstriction syndrome (RCVS). Evidence on the long-term outcomes of future vascular events and functional outcome after cSAH due to RCVS is limited. We aimed to assess the rates and baseline predictors of our primary outcomes (cSAH, intracerebral hemorrhage (ICH), and ischemic stroke), functional outcome, and mortality after cSAH attributed to RCVS. Individual patient data pooled analysis in patients with cSAH attributed to RCVS. A systematic literature search was conducted in PubMed and EMBASE. Two independent reviewers screened studies and extracted data. Quality assessment was assessed using the Newcastle-Ottawa Scale. Early events during the accepted time frame of an RCVS episode (<3 months) were classified as progression rather than recurrence. Follow-up was truncated at 5 years. Primary outcomes were recurrent cSAH, ICH, and ischemic stroke. Secondary outcomes were mortality and functional status measured by modified Rankin Score (mRS). We identified 21 eligible cohorts finally including 138 patients from 9 collaborative centers, which provided individual patient data. The mean age was 49.3 ± 12.1 years, and 110 (79.7%) were female. During a mean follow-up of 1.8 years, annual rates were cSAH recurrence 0.81% (95% CI 0.1-2.91), ICH 0.81% (95% CI 0.1-2.91), and ischemic stroke 0.81% (95% CI 0.1-2.91). Progression during the initial episode (shortly after admission) occurred in 10 patients for cSAH, 2 for ICH, and 8 for ischemic stroke, respectively. Of 106 patients (76.8%) with available outcome data, 100 (94.3%) achieve a mRS of ≤1 at follow-up, indicating no significant disability. Two patients died (annual rate 0.5%, 95% CI 0.09-2.9): one within 10 days and the other within 2 months of the cSAH. Our data suggest a favorable prognosis for most patients after RCVS-associated cSAH with low rates of recurrent events and a high proportion achieving functional independence. Major limitations include retrospective data collection and potential selection bias from centers providing individual patient data. Nevertheless, these findings provide prognostic information to inform clinical practice.


  • STAY-HOME: Endovascular Thrombectomy for Patients With Prestroke Disability

    by Jason Vuong, Thanh G. Phan, Bernard Yan, Peter J. Mitchell, Stephen M. Davis, Masatoshi Koga, Kazunori Toyoda, Teruyuki Hirano, Shinichi Yoshimura, Henry Ma

    Thrombectomy significantly improves clinical outcomes in patients with large vessel occlusion. However, the foundational trials used restrictive criteria, excluding patients with prestroke disability and included a few elderly patients (>80 years old). In addition, results from registries demonstrated conflicting results. We propose that there is equipoise for the elderly and prestroke disability to undergo thrombectomy and that trials are urgently required to guide treatment.


  • Open Access

    Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies

    by Andy Lim, Henry Ma, S. Claiborne Johnston, Shaloo Singhal, Subramanian Muthusamy, Yongjun Wang, Yuesong Pan, Shelagh B. Coutts, Michael D. Hill, Angel Ois, et al.

    Background: Risk of recurrence after minor ischemic stroke is usually reported with transient ischemic attack. No previous meta‐analysis has focused on minor ischemic stroke alone. The objective was to evaluate the pooled proportion of 90‐day stroke recurrence for minor ischemic stroke, defined as a National Institutes of Health Stroke Scale severity score of ≤5. Methods and Results: Published papers found on PubMed from 2000 to January 12, 2021, reference lists of relevant articles, and experts in the field were involved in identifying relevant studies. Randomized controlled trials and observational studies describing minor stroke cohort with reported 90‐day stroke recurrence were selected by 2 independent reviewers. Altogether 14 of 432 (3.2%) studies met inclusion criteria. Multilevel random‐effects meta‐analysis was performed. A total of 6 randomized controlled trials and 8 observational studies totaling 45 462 patients were included. The pooled 90‐day stroke recurrence was 8.6% (95% CI, 6.5–10.7), reducing by 0.60% (95% CI, 0.09–1.1; P =0.02) with each subsequent year of publication. Recurrence was lowest in dual antiplatelet trial arms (6.3%, 95% CI, 4.5–8.0) when compared with non‐dual antiplatelet trial arms (7.2%, 95% CI, 4.7–9.6) and observational studies 10.6% (95% CI, 7.0–14.2). Age, hypertension, diabetes, ischemic heart disease, or known atrial fibrillation had no significant association with outcome. Defining minor stroke with a lower National Institutes of Health Stroke Scale threshold made no difference – score ≤3: 8.6% (95% CI, 6.0–11.1), score ≤4: 8.4% (95% CI, 6.1–10.6), as did excluding studies with n<500%–7.3% (95% CI, 5.5–9.0). Conclusions: The risk of recurrence after minor ischemic stroke is declining over time but remains important.


  • Open Access

    Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

    by Thanh G. Phan, Rebecca Lim, Mirja Krause, Siow T. Chan, Hannah McDonald, Poh-Yi Gan, Shenpeng R. Zhang, Liz J. Barreto Arce, Jason Vuong, Tharani Thirugnanachandran, et al.

    Corrigendum: Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)

  • Open Access

    Determining the sensitivity of emergency dispatcher and paramedic diagnosis of stroke: statewide registry linkage study

    by Amminadab L. Eliakundu, Dominique A. Cadilhac, Joosup Kim, Monique F. Kilkenny, Kathleen L. Bagot, Emily Andrew, Shelley Cox, Christopher F. Bladin, Michael Stephenson, Lauren Pesavento, et al.


  • Open Access

    Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial

    by Nawaf Yassi, Henry Zhao, Leonid Churilov, Bruce C V Campbell, Teddy Wu, Henry Ma, Andrew Cheung, Timothy Kleinig, Helen Brown, Philip Choi, et al.

    Rationale Haematoma growth is common early after intracerebral haemorrhage (ICH), and is a key determinant of outcome. Tranexamic acid, a widely available antifibrinolytic agent with an excellent safety profile, may reduce haematoma growth. Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units (STOP-MSU) is a phase II double-blind, randomised, placebo-controlled, multicentre, international investigator-led clinical trial, conducted within the estimand statistical framework. Hypothesis In patients with spontaneous ICH, treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo. Sample size estimates A sample size of 180 patients (90 in each arm) would be required to detect an absolute difference in the primary outcome of 20% (placebo 39% vs treatment 19%) under a two-tailed significance level of 0.05. An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients. Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours; or matching placebo. Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours, defined as either ≥33% relative increase or ≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan. Discussion We describe the rationale and protocol of STOP-MSU, a phase II trial of tranexamic acid in patients with ICH within 2 hours from onset, based in participating mobile stroke units and emergency departments.


  • Top Cited Papers

    Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

    by Henry Ma, Bruce C.V. Campbell, Mark W. Parsons, Leonid Churilov, Christopher R. Levi, Chung Hsu, Timothy J. Kleinig, Tissa Wijeratne, Sami Curtze, Helen M. Dewey, et al.

    The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging.